Literature DB >> 8144553

Gelonin analogs with engineered cysteine residues form antibody immunoconjugates with unique properties.

M Better1, S L Bernhard, D M Fishwild, P A Nolan, R J Bauer, A H Kung, S F Carroll.   

Abstract

We engineered the ribosome inactivating-protein gelonin (Gel) to generate a family of Gel analogs, each with a single unpaired cysteine residue. The cysteine sites coincide with surface-accessible loops in the probable three-dimensional structure of Gel, or with the positions of endogenous cysteine residues. In most cases, enzymatic activity in vitro was unaltered by this modification. The rGel analogs were conjugated via their unpaired cysteine residue to the anti-CD5 antibody H65, or to H65 Fab and F(ab')2. Several rGel analogs formed immunoconjugates that were up to 6-fold more cytotoxic to antigen-bearing cells than those made with linker-modified rGel, whereas others were less potent. In the rat, the in vivo clearance rates of whole antibody conjugates correlated with their relative in vitro disulfide bond stability, and deconjugation to intact antibody and rGel was the predominant clearance mechanism. Fab conjugates to rGel analogs which differed in their in vitro disulfide bond stability had similar serum clearance rates, suggesting that clearance occurs mainly by removal of intact immunoconjugate from the serum, and is less dependent on deconjugation. Our results demonstrate that rGel analogs with a single cysteine at various positions on the solvent exposed surface are produced efficiently in Escherichia coli (>1 g/liter), and that the position of the cysteine greatly influences the potency and stability of the resulting immunoconjugates.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8144553

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies.

Authors:  Gautam Borthakur; Michael G Rosenblum; Moshe Talpaz; Naval Daver; Farhad Ravandi; Stefan Faderl; Emil J Freireich; Tapan Kadia; Guillermo Garcia-Manero; Hagop Kantarjian; Jorge E Cortes
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

2.  Characterization of the increased cytotoxicity of gelonin anti-T cell immunoconjugates compared with ricin A chain immunoconjugates.

Authors:  D M Fishwild; H M Wu; S F Carroll; S L Bernhard
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

3.  Improved Synthesis and In Vitro Evaluation of an Aptamer Ribosomal Toxin Conjugate.

Authors:  Linsley Kelly; Christina Kratschmer; Keith E Maier; Amy C Yan; Matthew Levy
Journal:  Nucleic Acid Ther       Date:  2016-05-26       Impact factor: 5.486

4.  Delivery systems for in vivo use of nucleic Acid drugs.

Authors:  R R Resende; H A M Torres; K K Yuahasi; Majumder P; Ulrich H
Journal:  Drug Target Insights       Date:  2007-08-09

Review 5.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 6.  Aptamers as therapeutics.

Authors:  Anthony D Keefe; Supriya Pai; Andrew Ellington
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

7.  Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.

Authors:  R R French; C A Penney; A C Browning; F Stirpe; A J George; M J Glennie
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.